Table 3.

Comparison between 8 patients who developed HCC and 551 who remained tumor-free during surveillance


Features

Patients who developed HCC, n = 8

Patients who did not develop HCC, n = 551

P
Hemophilia A (%)   6 (75)   452 (82)   2  
Hemophilia B (%)   2 (25)   57 (10)   NS  
Other coagulopathies (%)   0   42 (8)   NA  
Age, y (range)   56 (51-69)*  39 (14-88)  < .001  
Age at infection, y (range)   33 (18-55)   9 (0-62)   < .001  
Duration of infection, y (range)   21 (13-36)   26 (14-65)   NS  
Cirrhosis (%)   8 (100)   58 (11)   < .001  
Alcohol intake, more than 80 g/d (%)   3 (37)   35 (6)   < .05  
AFP level at entry, ng/mL (range)   6 (3-26)   2 (0.1-82)   < .005  
ALT level at entry, IU/L (range)   127 (53-206)   65 (5-645)   < .05  
HBV infected (%)   1 (12)   26 (5)   NS  
HIV infected (%)   1 (12)   126 (23)   NS  
Interferon treatment (%)
 
0
 
121 (22)
 
NS
 

Features

Patients who developed HCC, n = 8

Patients who did not develop HCC, n = 551

P
Hemophilia A (%)   6 (75)   452 (82)   2  
Hemophilia B (%)   2 (25)   57 (10)   NS  
Other coagulopathies (%)   0   42 (8)   NA  
Age, y (range)   56 (51-69)*  39 (14-88)  < .001  
Age at infection, y (range)   33 (18-55)   9 (0-62)   < .001  
Duration of infection, y (range)   21 (13-36)   26 (14-65)   NS  
Cirrhosis (%)   8 (100)   58 (11)   < .001  
Alcohol intake, more than 80 g/d (%)   3 (37)   35 (6)   < .05  
AFP level at entry, ng/mL (range)   6 (3-26)   2 (0.1-82)   < .005  
ALT level at entry, IU/L (range)   127 (53-206)   65 (5-645)   < .05  
HBV infected (%)   1 (12)   26 (5)   NS  
HIV infected (%)   1 (12)   126 (23)   NS  
Interferon treatment (%)
 
0
 
121 (22)
 
NS
 

NS indicates not significant; NA, not applicable.

*

Age at the time of HCC diagnosis.

Age at the end of the 6-year surveillance.

Close Modal

or Create an Account

Close Modal
Close Modal